Hi Sammy65,
I would agree to disagree with you on CAR-T: I would describe it as personalised immunotherapy.
I agree with you that CAR-T has the big advantage of being ‘once and done’ with implications for everything from the side effects being shorter term to easier logistics (fewer hospital trips).
I have been looking at papers from the latest ASCO (cancer conference) in Chicago. Phase 1 results of in vivo CAR-T treatment KLN-1010 are looking promising: 18 patients all MRD negative (no myeloma cells detected although – before readers of this get too excited – some are probably lurking) so far and side effects have not been too bad.
Regards
Rabbit